--- type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/100000000760769.md" description: "๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $Tempus AI(TEM.US) Tempus AI Partners With Angiosarcoma Awareness to Advance Rare Cancer Research๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โžค ๐“๐ž๐ฆ๐ฉ๐ฎ๐ฌ ๐€๐ˆ partnered with ๐€๐ง๐ ๐ข๐จ๐ฌ๐š๐ซ๐œ๐จ๐ฆ๐š ๐€๐ฐ๐š๐ซ๐ž๐ง๐ž๐ฌ๐ฌ to accelerate rare cancer research.โžค Collaboration will leverage Tempus' ๐ฆ๐จ๐ฅ๐ž๐œ๐ฎ๐ฅ๐š๐ซ, clinical, and AI analytics capabilities.โžค Dataset includes approximately ๐Ÿ”๐ŸŽ๐ŸŽ de-identified angiosarcoma patient records.โžค Each record contains paired ๐ƒ๐๐€ and ๐‘๐๐€ sequencing data with clinical information where available.โžค The dataset represents one of the ๐ฅ๐š๐ซ๐ ๐ž๐ฌ๐ญ known molecular resources for angiosarcoma.โžค Angiosarcoma affects about ๐Ÿ,๐ŸŽ๐ŸŽ๐ŸŽ people annually in the United States.โžค Research aims to identify ๐๐ข๐ฌ๐ž๐š๐ฌ๐ž ๐›๐ข๐จ๐ฅ๐จ๐ ๐ฒ and potential therapeutic opportunities.โžค Collaboration builds on the ๐€๐ง๐ ๐ข๐จ๐ฌ๐š๐ซ๐œ๐จ๐ฆ๐š ๐๐ซ๐จ๐ฃ๐ž๐œ๐ญ launched in 2017.๐Ÿ‘‰ ๐–๐ก๐ฒ ๐ˆ๐ญ ๐Œ๐š๐ญ๐ญ๐ž๐ซ๐ฌ:โžค Larger datasets could improve ๐ฉ๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐ฆ๐ž๐๐ข๐œ๐ข๐ง๐ž for rare cancer patients.โžค Collaboration may accelerate ๐ญ๐š๐ซ๐ ๐ž๐ญ ๐๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ and future treatment development.โžค Demonstrates Tempus AI's expanding role in ๐€๐ˆ-๐๐ซ๐ข๐ฏ๐ž๐ง oncology research.๐Ÿ‘‰ ๐„๐ฑ๐ฉ๐ž๐ซ๐ญ ๐’๐ญ๐š๐ญ๐ž๐ฆ๐ž๐ง๐ญ:โžค "Angiosarcoma, like many rare cancers, has been understudied because the foundational knowledge needed to develop novel therapy has been limited. Precision medicine should not be limited by the availability of data, especially for patients with uncommon and aggressive cancers. By bringing together Tempus' multimodal molecular and clinical data with collaborative research efforts across the healthcare community, we can fulfill the promise of precision medicine by treating the right patient with the right therapy at the right time." โ€” ๐„๐ณ๐ซ๐š ๐‚๐จ๐ก๐ž๐ง, MD, Chief Medical Officer of Oncology at Tempus.โžค "Rare cancer research has long been constrained by scale. Patients are geographically dispersed, data is fragmented across institutions and no single organization sees enough cases to answer many of the most important biological and clinical questions. Tempus has assembled an extraordinary molecular and clinical oncology dataset, and the Angiosarcoma Project at the Broad Institute of MIT and Harvard has built one of the largest patient-partnered rare cancer resources in the world. Together, we have an opportunity to create an unprecedented view of angiosarcoma that could reveal new disease biology, identify therapeutic opportunities and establish a model for how collaborative data sharing can accelerate discovery across rare cancers." โ€” ๐‚๐จ๐ซ๐ซ๐ข๐ž ๐๐š๐ข๐ง๐ญ๐ž๐ซ, CEO of Angiosarcoma Awareness, Inc" datetime: "2026-06-25T12:35:40.000Z" locales: - [en](https://longbridge.com/en/topics/100000000760769.md) - [zh-CN](https://longbridge.com/zh-CN/topics/100000000760769.md) - [zh-HK](https://longbridge.com/zh-HK/topics/100000000760769.md) author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)" generator: "portal-rs" --- # ๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $Tempus AI(TEM.US) Tempus AI Partners Wโ€ฆ ### Related Stocks - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**